Introduction
Personalized medicine is expanding quickly. In the last decade, it has grown to become an essential topic for physicians, health care organizations and the public [1] [2] [3] [4] . Since this expression is singularly widespread, Redekop and Mladsi [4] reviewed its various occurrences since its first reference by Gibson [5] to propose the following definition: "the use of the combined knowledge (genetic or otherwise) about a person to predict disease susceptibility, disease prognosis, or treatment response and thereby improve that person's health." This rationale underscores the fact that medicine was mindful of individual factors in clinical decision making well before genetic information was available. Recent developments such as the Human Genome Project have allowed personalized medicine to take one step further by enabling medicine to find the "therapy with the right drug at the right dose in the right patient" [6] . Such personalized medicine has great potential and is expected to contribute to improving health care management and reduce societal costs [7] .
Genetic testing is now a key element of modern personalized medicine. The "treatment fit" that pharma-
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Abstract
In this study, we contribute to the personalized medicine and health care management literature by developing and testing a new participative design approach. We propose that involving gastroenterologists in the development of a predictive test to assist them in their clinical decision-making process for the treatment of inflammatory bowel diseases will increase the likelihood of their acceptance of the innovation. Based on data obtained from 6 focus groups across Canada from a total of 28 physicians, analyses reveal that current tools do not enable discriminating between treatment options to find the best fit for each patient. Physicians expect a new predictive tool to have the capability of showing clear reliability and significant benefits for the patient, while being accessible in a timely manner that facilitates clinical decisions. Physicians also insist on their key role in the implementation process, hence confirming the relevance and importance of participative designs in personalized medicine.
cogenomics facilitates is beneficial for the patients, who may avoid the side effects of many treatments, as well as for health care systems, which do not have to cover the costs of ineffective therapies. Availability of such testing has grown rapidly in the last decades [8] . However, many physicians report their unfamiliarity with pharmacogenomics testing and its role in therapeutic decision making [9, 10] . Taber and Dickinson [8] even observed confusion about the purpose of pharmacogenomics testing and the process of test ordering and interpretation. This lack of clarity concerning the process and value of predictive tests may deprive patients from technologies that may benefit their health as well as societies from practices that could assist their financial performance as a whole. Even though the decision of listing the tests or not for reimbursement is taken upstream, the physicians are those ultimately responsible for their transfer into patients' clinical decision making [11] . There is a need to understand the reasons for which physicians do not currently fully take on pharmacogenomics.
Clinical practice guidelines are common exercises destined to help health care providers by synthesizing the literature on health care management practices, such as predictive testing, into specific recommendations for care [12] . Najafzadeh et al. [13] hinted that the lack of clinical guidelines and protocols on the use of genomic tests are a key issue in health care management. According to DiMagno et al. [14] , the implementation of the same guideline recommendations is variable among physicians. This "evidence-to-care" gap highlights the need for better knowledge of other potential translation strategies.
An excellent example of this aforementioned gap is the treatment of inflammatory bowel diseases (IBD). Rocchi et al. [15] argued that, as part of chronic diseases, IBD is highly amenable to personalized medicine since it represents one of the best-described common diseases from a genetic standpoint. These represent "a group of disorders that cause segments of the gastrointestinal tract to become inflamed and ulcerated. An abnormal response of the body's immune system plays a role in each of the two main forms of IBD: Crohn's disease (CD) and ulcerative colitis (UC)" [15] . Several drugs are available to treat IBD. However, physicians are currently unable to predict which drug would be the most effective for a given patient. As an example, for some biologic therapies such as anti-TNF agents, studies show that up to 2 out of every 5 IBD patients will not respond [16, 17] . Distinguishing patients that respond to biologics from nonresponders would lead to improved therapeutic response rates, better clinical and endoscopic outcomes, less tissue damage (hence reducing the need for surgery), and a decrease in societal costs due to a lack of patient productivity. Even though pharmacogenomics looks promising by using a predictive test in such cases, development of such an innovation would be useless if specialized health care actors, including in particular the treating physicians, do not adopt it in their daily routines.
Plainly, clinical practice guidelines alone have not proven to be the most effective way to entice physicians to use predictive tests. The present study attempts another promising path to involve physicians in the implementation of an innovation such as predictive testing. Known as participative design (PD), this approach has been the focus of ongoing research in different streams of innovation management, marketing, and design for the past 45 years in Europe and America [18] . Briefly, based on the general theory of co-creation, PD is a specific type of approach that favors a high involvement of stakeholders in the design and outcomes of innovations. In addition to the benefits associated with an improved implementation rate, one reason behind the choice of this type of design is that while many current studies investigate the properties of innovations in personalized medicine, the vast majority of these studies are strictly empirical in nature and are not grounded in a solid theoretical background that makes room for generalizations. Such a theoretical background in innovation management would be most helpful and relevant to make sense of the voluminous empirical literature that questioned doctors about what they would like out of personalized medicine and the conditions that would help them fully incorporate these tools into their current practice.
Purpose of the Study
The purpose of this study is to involve physicians in the PD of a genetic predictive test for the treatment of IBD. Specifically, its goal is to answer the following question: How can research and development teams co-create a predictive test with gastroenterologists to assist their clinical decision making for the personalized treatment of IBD?
In order for physicians to propose the most important design features for them, they first have to verbalize their current practice to help them point to the gaps they see between what they have and what they need. These gaps represent the first step in a PD that will ultimately result in the adoption of a genetic predictive test that will facilitate clinical decision making for the treatment of IBD. In accordance with this approach, the objectives of this study were as follows: 1. To understand the current practices leading to a therapeutic decision for an IBD 2. To learn about physicians' perceptions and level of satisfaction with current practices 3. To investigate physicians' expectations towards characteristics of a genetically based predictive test that could assist them with personalized treatment decision making The paper is organized as follows: First, the literature on innovation management, clinical decision making, and personalized medicine is reviewed. This paper argues that limitations concerning the latter 2 objectives can be addressed through a PD and subsequently proposes an integrated model for this study. Second, the method is presented and discussed. The results of the study, supported by relevant quotes by the participants and tables summarizing the coding process outcome, are then presented. Lastly, implications for theory and practice are discussed in the concluding sections.
Theoretical Background
The subject of this study, namely the exploration of a PD approach for predictive testing, requires a conceptual framework located at the junction between innovation management and health care management. First, the PD will be positioned among the several streams of research on innovation management as a type of participative innovation, which in turn is a type of co-creation in the global field of the innovation process. Issues surrounding current clinical decision-making processes of physicians, generally and in the context of personalized medicine, will be developed and linked with the potential benefits of a PD. An integrated PD model applied to physician's clinical decision making for personalized medicine summarizes and concludes the theoretical background of this study.
Innovation Process
Pharmacogenomics are relatively innovative in their nature. Lee et al. [19] defined innovation as "any new idea or approach that is applied in fundamentally different ways to create value for the organization and other stakeholders such as customers, suppliers, partner organizations, communities, governments, or even general good of humanity. Thus, innovation is directly tied to value creation" [19] . Value creation can take many forms, but in the current framework of health care management, we have chosen to follow the definition of Porter [20] : "Achieving high value for patients must become the overarching goal of health care delivery, with value defined as the health outcomes achieved per dollar spent. This goal is what matters for patients and unites the interests of all actors in the system. If value improves, patients, payers, providers, and suppliers can all benefit while the economic sustainability of the health care system increases." There are many paths to innovations that may create value in health care systems [19] . However, due to the main influence of physicians in the provision of care for patients, a co-creation process was integrated in this study to ensure their involvement in the development and success of the innovation.
Co-Creation
Co-creation is broadly defined as "the creation of value by consumers" [21] . While consumer involvement in the innovation process has been occurring since the 1970s, mainly in Scandinavia, the approach has significantly grown in the last decade to include a variety of forms and labels. This approach is based on a democratic process of dedicated activity that takes people's practices and needs as a starting point to generate business opportunities in the form of products and services. These opportunities are developed through an ongoing collaboration between the people that they address and the companies in charge of their realization [22] . Participative innovation is the general philosophy behind two streams of research, namely, PD -as developed in Scandinavia -and a more recent American trend: co-design. This latter trend is meant to help researchers, designers, and users to jointly make things that include items such as sketches, mockups, or prototypes. Since the development of predictive tests is less likely to emerge from the co-design approach, the present project was based on the long-standing Scandinavian PD approach.
Participative Design
As part of a co-creation approach, PD attempts to bridge the gap between researchers, designers, and users by organizing cooperation among them [18, 23] . Ideally, users are involved from the beginning of a venture as well as during its iterations, and they contribute dynamically and creatively in a multidisciplinary setting [22] . PD arose as a way to address the issue that designers of technologies often knew very little about the end users' work and practice circumstances. It was also a means of guaranteeing that technologies supported and improved end users' knowledge and skills rather than redefining people's trades through the introduction of new technologies into their workplace. However, in order to ensure that PD can be efficiently implemented, information must flow easily between the developers and the adopters of innovation; such a process reduces the cost as well as time and risk inherent to innovation diffusion. PD is, therefore, a design approach, which is different from other approaches such as market research in which users are only invited to evaluate a finished product. The early involvement of users has positive effects on both system success and user satisfaction [24] .
Health care management literature also refers to the involvement of stakeholders. As previously stated, physicians are the gatekeepers between the innovations of personalized medicine and patient care. It is expected that the PD approach could fill some of the "evidence-to-care" gaps between guidelines and the actual care given to patients reported in the health care management literature.
Clinical Decision Making
Literature in health care management highlights many factors that influence the clinical decision-making process of a physician as well as those that could motivate a change in this process. The theoretical basis for change in clinical practice among physicians when selecting a test or a treatment can be grouped into the following 4 components: organizational context; patient factors; physician factors; and evidence-based medicine. First, Sanders et al. [25] highlighted the importance of coherence between organizational and interpersonal factors that may help explain the dynamics of implementation. Other environmental factors, such as the impact of availability of diagnostic tools in remote areas [26] and the remuneration system [27] , influence physicians' decisions. Then, the process of clinical decision making in the context of personalized medicine underscores the essential role of patient factors, such as quality of life, education, and communication [28] [29] [30] [31] [32] .
Also important are the organizational and individual factors, as the decision over clinical decision making ultimately resides in the physicians' hands. Research shows that the physicians' education and experience both influence their decision-making process, including their adherence to practice guidelines [13, [33] [34] [35] . Empirical findings on test adoption by physicians highlight specific issues to consider while introducing such innovations [36] [37] [38] [39] . The development of a predictive test through PD building on the physician's experience and involving them in evidence-based medicine is likely to encourage them to incorporate this tool into their practice. To the best of the authors' knowledge, such an approach has yet to be attempted in the context of an empirical study.
Personalized Medicine
Physicians generally recognize the need to personalize their treatments to the characteristics of their patients [2] . However, as stated above, there are several barriers to the complete integration of personalized medicine into general practice. Studies conducted in Canada by Najafzadeh et al. [13, 40] concluded that the nature of the genetic tests and their availability, the training and guidelines surrounding genetic testing and the issues surrounding the complexity of gene expression and validity of genetic tests, represent the major concerns of physicians concerning the implementation of pharmacogenomics as part of their clinical practice. Wideroff et al. [41] used the results of a national survey in the United States to deter- mine the prevalence of using cancer susceptibility tests by physicians and to assess demographic variables associated with their use. They suggested that the validity of the test, confidentiality, and affordability are among the most prevalent concerns about genetic testing. Finally, Suther and Goodson [42] illustrated how physicians' perceptions about the characteristics of genetic tests influence the likelihood of adopting genomic medicine in their practice. They reported that the barriers identified most frequently in their literature review were inadequate knowledge of basic genetics; lack of detailed or updated family histories; lack of confidence; and lack of referral guidelines. The present study aims to find an approach to remove most of the barriers to the adoption of a predictive test listed above in the context of IBD treatment and management. PD goes beyond simply investigating the obstacles of personalized medicine. As shown in Figure 1 , this study proposes that allowing physicians to mobilize their current practices leads them to identify their primary needs and expectations concerning their clinical decision making and, consequently, their decision whether to utilize predictive testing ( Fig. 1 ) .
Methodology

Study Design
The present study is part of a larger research project on IBD including both UC and CD in Canada. Its goal is to deepen the understanding of the physician treatment decision-making process in order to maximize the integration of predictive tests that might be developed to personalize IBD patient care. With such a goal, it is considered an exploratory study for which a focus group method is appropriate [43] to reveal the characteristics of the "evidence-tocare" gap and to encourage the emergence of the ideal characteristics of the tools and medical practice through interactions among participants. The focus group methodology involves engaging a small number of people in informal group discussions, focused around a particular topic or set of issues [44] . The informal nature of this method, as compared to questionnaires, creates a less intimidating situation and a freedom that emboldens participants to be more forthcoming [45] as well as to explore matters that the participants recognize as significant [46] . Overall, focus groups enable a collaborative discussion and reflection that is difficult to accomplish by other techniques [47] . Additionally, physicians are used to working in groups, and enabling discussions in circumstances with which they are familiar may allow them to express themselves more extensively about the issues and their opinions on the topic at hand.
Participants
An estimated 233,000 Canadians suffer from IBD (UC = 104,000 and CD = 129,000), which would rank Canada among the countries with the highest IBD rates in the world. There are 765 gastroenterologists in Canada treating patients suffering from these diseases [48] . The data were collected from gastroenterologists to identify the perceptual gap between the current treatment selection process and the potential use of a genetic predictive tool to assist them in their decision regarding personalized treatment.
In order to reach the targeted physician population, the organizers of two major gastroenterology conferences were contacted, namely the Canadian Association of Gastroenterology and the Québec Association of Gastroenterologists. They sent their members an invitation and follow-up reminders to participate in our study during their annual meeting. Respondents were then asked to help organize a focus group with their local colleagues in their hometowns. Even though qualitative studies do not require the sample to be representative [49] , every effort was made to ensure a diversity of physicians in terms of province of origin, years of experience, and gender. However, the gastroenterologists were all invited, and participation was on a volunteer basis. Six focus group interviews that included a total of 28 gastroenterologists were held. The characteristics of the participants are presented in Table 1 .
Interviews and Data Collection
An interview guide for the focus groups was drafted, as summarized in Table 2 . Discussions lasted approximately 60 min and covered the following themes: the treatment decision-making process, perceptions of current clinical guidelines and available tests, as well as perceptions toward genetic tests. Each group session was led by one moderator accompanied by a research assistant who covered each of the themes in the interview guide, which concluded with final reflections and a summary of our impressions. Each focus group interview was recorded, anonymized, and subsequently transcribed by a professional bilingual transcription firm.
Ethics
Based on the approval and recommendations from the researchers' university ethics committees, all relevant documentation was sent to potential participants of the study prior to the focus group sessions during the recruitment phase. At the start of each focus group session, the participants were informed on the project in accordance with the focus group interview guide, as shown in Table 2 . They were also given a printed document that included information on the aim of the study, anonymity issues, and a field for signing an informed consent. The focus group sessions only proceeded forward once all participants had agreed to participate in the study.
Data Analysis
The focus group discussions were recorded, and then transcribed and verified by an external resource. Then, a tree node using the different categories brought up by the operational framework was developed in order to allow for uniform coding by the research team members and to ensure internal validity with the QDA Miner software. The individual coding process involved detailed coding of the text segments (meaning units), followed by the coding of related meaning units ( i.e. , categories) and related categories ( i.e. , themes) [44, 47, 50] . Two individuals from the research team coded them verbatim in line with the preestablished tree node. A cross-verification of the coding was done to ensure neutrality and similarity. 
Results
A total of 28 gastroenterologists participated in our study ( Table 1 ) . Among these participants, men outnumbered women by a ratio of more than 3: 1, which somewhat accurately reflects the overall gender distribution among Canadian gastroenterologists (71% male and 29% female) [48] . Given that the provinces of Nova Scotia and Saskatchewan have only a few gastroenterologists (23 and 13, respectively), this distribution is represented in our study (1 and 2, respectively) . The higher number of participants from British Columbia, Québec, and Ontario also reflect the relative proportion of gastroenterologists in those provinces (72, 224, and 272, respectively). All but 2 participants in our study were certified Fellows of the Royal College of Physicians of Canada (1 non-Fellow MD and 1 PhD), which is consistent with the numbers (100%) reported for the overall population of gastroenterologists. All of the participants were affiliated with a public hospital, clinic, or health science center (the participant with the PhD was a researcher), which is representative of the overall population of gastroenterologists (91%). In terms of age distribution, the majority of the participants (37%) were in the 35-to 44-year age bracket, 32% were aged 55 years and over, and 21% were between 45 and 54 years of age. Thus, most of the characteristics of our sample were, therefore, representative of the overall population of Canadian gastroenterologists.
Physicians are in the best position to discuss their own practice, and the tools they deem most appropriate to assist them in their clinical decision making. In accordance with a PD approach, the discussions allowed the participants to initially go over the daily issues associated with the treatment of IBD and the current tools available to facilitate their decision-making process. Missing tools and gaps in knowledge emerged from these discussions, and gastroenterologists were given the opportunity to align these gaps with what they considered to be the essential characteristics of a predictive test designed for the treatment of IBD.
Current Practice among Canadian Gastroenterologists concerning IBD Treatment Decision Making
Current practice among Canadian gastroenterologists in IBD treatment decision making generally includes two approaches. The first is the traditional approach to the treatment decision-making process, which follows the standard treatment escalation pyramid, as described in the following quote from a participant: "…there's a step-wise approach [in which] efficacy and safety are probably inverse, so the less effective, the safer it is, within reason. It's how severe and therefore, whereabouts on the ladder you can start and how quickly you need to do something. That'll determine how far you jump in. Generally, one's not going to go straight to biologics, unless somebody has a severe form of colitis…" (OH6)
In some circumstances, physicians can also choose to accelerate the progression on the treatment pyramid, as the following quotes from participants show:
"IBD patients are such a huge spectrum that they don't always fit nicely into one little... […] the guidelines are good general things to have there but don't provide answers […] It's more complicated than that." (SK5)
"Today, we know that the more that you wait for this kind of patient to initiate a biological agent, the more you risk obtaining a response that is not as perfect as if you had been ready from the start.
[…] Today, though, we have a more proactive approach then it's more... Each patient is unique, but we know this kind of patient there, we must act quickly." (QQ1)
While the traditional stepwise approach is favored in the official guidelines, there is a growing recognition that the second approach, personalized care, yields better results than a "one-size-fits-all" tactic. However, personalized medicine requires individualized information that is not yet available for some aspects of the disease. Another element concerns the current gap in knowledge and practice experienced by physicians regarding missing tools, both in terms of optimizing treatment effectiveness and eliminating ineffective treatment options, as the following quotes suggest: "It's just all over the place. It's just really hard to tell, and I don't think these other tests tell us. Even when we have the whole colon out, they get it wrong." (BV4)
"Each time we choose, we think of the right molecule, but also the patient is exposed to risks. If, from the start, we knew that you did not need to run that risk and to seek more benefits, then for sure that is the dreamed tool there." (QQ1) "We have certain tools like TPMT that can judge the risk of an agent. We don't have any diagnostic tools that can tell us the chance of an agent working better than other. We have no prognostic factors for how effective these agents will work." (BV4)
The participants were generally confident in their arsenal of treatment options and trusted their judgment in choosing to follow the standard treatment escalation or to accelerate the progression in more severe cases. What emerged as missing in their daily practice are tools that could help them choose the best treatment for each patient, and enable them to avoid both the dangers of undertreating the disease thereby letting the condition deteriorate, and the dangers of overtreatment that would ex-pose patients to inappropriate treatments and long-term side effects. Table 3 presents all aggregated meaning units for the first theme identified above.
Satisfaction toward the Current Use of Available Predictive Tools
The second theme relates to the questions as to if and how physicians use the currently available predictive tools to personalize their treatment and management of IBD patients (imagery, serology, and thiopurine methyltransferase [TPMT] levels). The first and second subthemes on this subject relate to the issues of accessibility and turnaround time referred to in the following excerpts:
"It all comes down to an accessibility issue; it's an issue of cost, really. If you have easy access and it doesn't cost that much, you'll use it much more often than in much more different circumstances. When it's limited, then we pick and choose what situations will help them the most. In our center, we can get it, but it's a bit of a hassle to get." (OT2A) "The challenge with us is the turnaround. We order the test, but we actually don't get it for a few weeks, so often it's not in a time frame that's helpful. We have to make a decision to start therapy. It adds another layer of complexity of... you have to give them a call back to get the result before they start the medication. Sometimes it gets bypassed for that reason." (OT2A)
The analysis of the discussions highlights inconsistencies regarding current tests in terms of availability, cost, and coverage as well as issues arising from the delays before the results can be interpreted. If the information is not received in a timeframe that is useful for the patient, the return on the financial investment made on the development and ordering of the tests is significantly diminished. The third subtheme concerning the physicians' satisfaction toward the current use of available predictive tools specifies the main reasons for which physicians 
Standard treatment escalation
The norm is to follow the treatment pyramid, which is a prudent, stepwise approach to treatment escalation, on which patients begin with the mildest options and then move on to more intensive treatments if needed The initial presentation of symptoms will dictate where the patients begin on the treatment pyramid, but the rhythm of the evolution of the disease also impacts the decision for the first and subsequent treatments Physicians also have to accommodate patients about their preferences and fears: issues of future pregnancy, ongoing studies, and fear of needles are some of the issues that need to be taken into consideration
Accelerated treatment pyramid
The severity of the symptoms exhibited may cause physicians to bypass the stepwise approach and move rapidly to more intensive treatments such as biologic agents Factors such as smoking, obesity, and poor life hygiene may also cause physicians to move quickly, since such patients are vulnerable to rapid disease degeneration The current norms of practice are evolving from the standard stepwise approach and favor more and more rapid movements to biologic agents and to let go of the traditional use of steroids to relieve acute symptoms
Missing tools Effectiveness of treatment
Every patient has specific pathways by which their disease can be managed: however, there are very few tools that can help physicians determine what pathway is currently the most effective for each patient There are reliability problems with current predictive tools that lead to physicians ordering them as a last recourse and not fully taking their results into account for treatment decision making
Elimination of ineffective treatment options
It is known by physicians that some patients will not respond to the strongest treatment options in their arsenal; however, they have no predictive tool that tells them which patient will not respond There are serious dangers of both over-and undertreating the disease of patients: exposure to serious, long-term side effects and worsening of symptoms can be caused by inappropriate treatment Veilleux et al. "If you do have a normal result, you'd just typically start with a full dose rather than having to do the 50 milligrams for two weeks and then go up. That's one of the advantages of having the ability to do the test, so you get off the bat." (OT2A) "It should be a standard of care when a patient has lost response to tell you what to do next because you have some very expensive and very potentially important decisions to make then." (OT3B) "It's almost like malpractice in our circles if you don't order it, but the reality is, it's actually quite rare that we act on it. Occasionally, we'll have some TPMT levels that suggest the person may be a heterozygote for the gene, but for the most part, I find that we function pretty much the way we always used to. Correct me if I'm wrong, but I think it's extremely rare that we modify our prescription based on the test." (OT2B)
One can see from the preceding quotes that even when physicians order tests as part of their standard of care, there can be underlying issues that lead them to not consider the results of the test in their clinical decision making, thereby invalidating the initial investment. These core issues resound with the last subtheme, which concerns the reasons for which physicians do not order tests that may predict response to treatment or incorporate them into their practice, as evidenced in the following quotes:
"They [serologic test, ANCA and ASCA] tend not to distinguish the people you need to distinguish." (BV4) "They're not sensitive and specific enough to warrant its use." (OH6)
" […] we have to come up with criteria to see in what instances it is going to actually make a difference because if it's not going to make a difference, there's no point in doing the test. And that's an expensive test." (BV4) Patients' loss of response In case of a patient's loss of response in his current treatment, predictive tests will be ordered before making a decision to move to a stronger treatment Optimization of treatments A concern regarding the optimization of treatment for the specific condition and symptomatology can drive physicians to order and use predictive tests
Reasons not to order tests Doubts on reliability Most physicians report concerns about the reliability and sensitivity of many predictive tests, notably that current tests fail to measure what they are supposed to measure and that they are not reliable enough for them to make an informed decision without other diagnostic tests and imagery tools Polygenetic nature of IBD Issues about the interaction of multiple genes in the symptomatology of IBD patients generate doubts whether a general predictive test could cover the variability in the presentation of the diseases Inadequate training Not all physicians are trained enough to understand the implications of the results of predictive tests and, as such, either do not order them or do not fully integrate them into their practice "Yeah, but I would not just say that, 'we have no time to read the studies': we don't have the knowledge or the training at the university to read the studies. At […] University, they didn't train us to read the studies properly, to make a critical analysis, to understand the meaning of a study." (QQ1) Based on the above, there appear to be many issues surrounding the current use of predictive tests; some are bound to the conditions surrounding the tests per se, and some are related to the nature of the test. A test that is accurate and reliable but not covered by public health care or that takes too long to produce results is less likely to be ordered. Along the same lines, a test that is cost-effective and has a quick turnaround time, but is associated with reliability issues, is also less likely to be fully incorporated into current practice. Some specific characteristics are needed in order for physicians to use predictive tools in a way that would be useful to them and to provide personalized care for IBD patients. Table 4 presents all aggregated meaning units for the second theme described above.
Ideal Characteristics of a Predictive Test
The final theme relates to the ideal characteristics and implementation conditions of any new predictive tool in the care of IBD patients. The first subtheme refers to the characteristics of such a tool and raises concerns about reliability, accessibility, real impacts on the patients' health care, and user friendliness, as described in the following quotes:
"It should be reliable, particularly. That would be the number one thing. If it really is going to be a test that will tell me that this patient will respond to anti-TNF or not, or any other choice, that certainly would be something that I would be very keen to use. Is it going to be something very helpful? Is it reliable?" (OT2A) "Yes, in the ideal world, if you had three different pathways, if it would actually give you a likelihood not just for one pathway, but for all three pathways, so you could compare them. At the end of the day, that would be the most useful." (OT2A)
"And it only cost $50. And if you could tell us by the end of tonight…" (BV4) "Ultimately, if you have a new tool, it would be great to integrate it with other clinical markers that we already have, so that it's not just learning a tool in isolation. Maybe there's a scoring system for the tools' importance." (OT2A)
These quotes underscore the importance not only of the relevance and reliability of the test, but also of its efficient integration as part of the tools and procedures that are already known and used. Cost and availability represent serious issues to consider, but if the test is reliable and easy to use, most physicians will incorporate it in their standard of care. The second subtheme refers to ideal conditions in which physicians could learn about the tool and how it can be implemented into their current practice. Issues of physician involvement, endorsement, and knowledge transfer are emerging as prominent, as the following quotes show:
"Reasonable framework, which you then have to have the knowledge and the experience to build on. I think what would help for a lot of that is being able to build on the experience we have, because what we all do is build individual experience, which is, to some extent, specific to the patients that we've seen." (OH6)
"From my point of view is that the evidence then is translated into something of a guideline and guideline endorsement by a respectable agency, and then bring out the algorithm for management and if it can be included in that, then I think it will be applicable to many people who just don't know the details and so on, but who control the recommendations of management." (OT3B) "Yeah, because, you know, this work, by successfully doing this, you will actually have publications. So that will be the first step that comes out, and then presentations at meetings, and going more locally to make sure that whoever didn't get to the meetings and missed that month's article gets to hear about it. It's gonna be a stepwise process." (BV4) "It's always nice if it comes from our peer group. It has to be delivered by the medical community.
[…] I think we listen to the leaders. The simpler the flow chart or the algorithm the better it is." (SK5) Based on the above, the construction of any new predictive tool would have to build on the weaknesses identified in current predictive tools, and be endorsed both by a well-designed controlled clinical trial and a reputable agency, as well as by peers and key opinion leaders, and published in trustworthy journals and conferences, in order to help physicians understand their utility in their management of IBD disease. Table 5 presents all aggregated meaning units on this last theme identified above.
Discussion
Participative Design
Since results show that physicians want to be involved in the development and integration of a test that may predict response to treatment, PD proves to be a relevant approach to involve physicians in the success of an innovation in personalized medicine. Even though earlier studies highlighted some of the issues raised by the physicians in the present study [13, 40-42, 51, 52] , none of these appear to reach beyond a strict description rooted in a broader theoretical and methodological design. Among the most commonly cited barriers to implementation in the present study, as well as in previous publications, are the lack of evidence-based guidelines, conviction in the validity of the test, and training. By involving physicians at the beginning of the development of a predictive tool led by a consortium of researchers, physicians are thus reassured that the developed test will take into account the issues that are relevant to them as well as the identified ideal characteristics. They will become experts on the matter and be able to train their colleagues with regard to its relevance in their practice. They will promote the innovations and find themselves in a key trustworthy position to fill the gap between the development of evidence-based guidelines -in which they will have been involved -and the provision of care in which they also have high stakes.
Clinical Decision Making and Personalized Medicine
The results of the present study are consistent with the health care management literature and clarify the four categories of factors that influence the clinical decisionmaking process of physicians in the specific case of personalized medicine: the organizational context, patient factors, physician factors, and evidence-based medicine. The perspectives of the clinicians interviewed regarding predictive genetic testing were mostly unanimous and complementary. No regional or gender-related trends were observed. However, since health care in Canada is managed at the provincial level, provincial test reimbursement policies influence and may account for regional differences in the use of a test. As stated above, the involvement of physicians in the development of a predictive test helps to fill the gap between clinical guidelines and actual practice in personalized medicine. As suggested by Najafzadeh et al. [13, 40] , along with the high rate of progress in genomic technologies as well as their Results from the clinical trials would need to be published in reputable peer-reviewed journals Conferences by experts or colleagues endorsing the predictive tool would also contribute to successful implementation Formal training in local hospitals to understand the interpretation of the test and its implications for practice and treatment decision making would also be helpful emerging clinical applications, the need for more recent information is unavoidable; rapid developments in the field may have modified physicians' perceptions, experiences, and views about pharmacogenomics. The present findings thus reinforce the factors highlighted by previous studies concerning the barriers to the implementation of personalized medicine by physicians in gastroenterology, albeit in Canada at the present time, thereby contributing to the growing body of knowledge in this field. The present study also contributes to the academic field of innovation management by adding pharmacogenomics as a new field of application. Although the characteristics thus far identified have been incorporated into the larger study in which the test will be developed, the development of this test has yet to be completed. Given that, to the best of our knowledge, no other model features this type of integration in other situations, this represents an initial exploratory step that we must further develop as part of future research. The approach used in this study proposes concepts that can be applied to other health technology development contexts. Physicians must, and indeed wish to, be involved in order to identify key characteristics to complement the currently available tools. They should also play a key role in transferring knowledge to their colleagues to gain their trust. Their participation throughout the process will facilitate the adoption of the predictive test and avoid the costs of going back to R&D to modify test characteristics to meet needs that were not expressed without their involvement.
Conclusion
The present study is relevant to several stakeholders who are involved in both innovation and health care management. Analyzing the topic of personalized medicine implementation is of great importance, first for firms involved in the development of pharmacogenomics as it increases the likelihood that their products will be ordered and used by physicians, and hence their return on investment in the development of these tools. Their products and services will be better suited to the reality of physicians by having the desired characteristics. Therefore, physicians will be more likely to routinely order the product with which they have been involved since the early development stages. This is an exploratory study in which we seek to deepen the understanding of the physician treatment decision-making process, in order to maximize the integration of predictive tests that may potentially be developed to personalize IBD patient care. It should be interpreted within the context of certain limitations. First, it focuses on a speciality field of medicine and specific diseases in a single country. While the data collected as part of this study clearly illustrate the perspectives of the clinicians interviewed regarding predictive genetic testing, the extent to which the present findings may be applied to understanding personalized medicine requires a broader assessment. Second, given that focus groups are considered qualitative studies, the samples are generally rather small. Moreover, research relying upon the perspectives of physicians is particularly challenging given their limited availability [53] . Notwithstanding the limited representativeness of the sample, we are nevertheless confident that the results of our exploratory study provide useful insights. The depth of the discussions achieved using the focus group approach, as well as the number of common mutual issues that were discussed regarding several themes, revealed general agreement among participants.
More research through longitudinal and quantitative studies will be needed in order to further address how PD could benefit personalized medicine. Insights from other stakeholders such as health technology assessment bodies should also be included. Future research should also explore the patients' perceptions of such predictive tools as well as issues associated with knowledge transfer aimed at implementing pharmacogenomics testing into clinical settings. Pharmacoeconomic studies could highlight the costs and benefits of such a technology in terms of monetary value, efficiency, as well as enhanced quality of life for the patients. 
